Slide 1: AACR 2026 Highlights
AACR 2026 Highlights Zai Lab April 20, 2026 NASDAQ:ZLAB | HKEX:9688 © 2026. Zai Lab. All Rights Reserved.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements relating to our strategy and plans; clinical development strategy and pipeline programs, particularly ZL-1310 (zoci), ZL- 6201, and ZL-1222; clinical development programs and related clinical trials; expected timing and
Slide 3: AACR 2026 Highlights: Presenters
AACR 2026 Highlights: Presenters Rafael Amado, MD Luis Paz Ares, MD, Ph.D. Rohit Thummalapalli, MD President, Head of Global Research and Chair of the Medical Oncology Assistant Attending Physician and Development, Zai Lab Department at the Hospital Universitario Gastrointestinal Medical Oncologist,
Slide 4: Disclosure Information
Disclosure Information Luis Paz Ares, MD, Ph.D. Rohit Thummalapalli, MD • Leadership / Equity Interests: ALTUM Sequencing, Stab • Institutional research funding: Zai Lab, Crinetics Therapeutics Pharmaceuticals • Consulting / Advisory Roles / Honoraria / Speakers’ • Advisory board participation/consu
Slide 5: Today's Agenda
Today’s Agenda Introduction Rafael Amado, M.D. Zocilurtatug Pelitecan (ZL-1310, Zoci) Highlights from AACR 2026 – SCLC and NEC Intracranial Activity of Zoci in SCLC Luis Paz Ares, M.D., Ph.D. Zoci in Neuroendocrine Carcinomas Rohit Thummalapalli, M.D. Zoci Clinical Development Plan Rafael Amado, M.D
Slide 6: Intracranial Activity of Zocilurtatug pelitecan in ES-SCLC with Brain Metastasis
Intracranial Activity of Zocilurtatug pelitecan in ES-SCLC with Brain Metastasis Luis Paz Ares, MD, Ph.D.
Slide 7: SCLC: Brain Mets Are Common, Occur Early, and Drive Poor Outcomes
SCLC Landscape SCLC: Brain Mets Are Common, Occur Early, and Drive Poor Outcomes Extensive-stage Small Cell Lung Cancer (ES-SCLC) is a high-grade neuroendocrine carcinoma characterized by early metastasis, Worse Survival Outcome in Patients with Brain Metastases aggressive clinical behavior, and p
Slide 8: Current Therapies Do Not Adequately Control CNS Disease
SCLC Landscape Current Therapies Do Not Adequately Control CNS Disease Current Standard of Care Lack of Effective Therapies that Address CNS Mets For symptomatic CNS mets Median Overall Survival Comparison Tumor volume WBRT Pts with CNS met ~3 mos1 Risk of rapid (all lines) progression of extracrani
Slide 9: Zoci May Be Uniquely Suited for Brain Metastases in SCLC
Zoci MOA Zoci May Be Uniquely Suited for Brain Metastases in SCLC Mechanistic Rationale for Zoci’s CNS Activity Targeted delivery to DLL3-expressing tumor cells Zoci Direct cytotoxic killing High payload delivery to target (DAR=8) Strong bystander effect may enhance activity in brain lesions
Slide 10: Intracranial activity of ZL-1310 in ES-SCLC with baseline brain metastasis
Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial Pedro Rocha1, Manish Patel 2, Yi-Long Wu3, Jun Zhao4, Grace Dy5, María Eugenia Olmedo García6, Qiming Wang7, Va
Slide 11: Background
Background • Zocilurtatug pelitecan (zoci) is a Delta-Like Ligand 3 (DLL3)-targeted antibody–drug conjugate (ADC), developed using the TMALIN® (Tumor Microenvironment-Activable LINker-payload) platform. • Efficient payload delivery to the targeted cells with DAR=8 • Potent bystander killing mediated
Slide 12: Study Design
Study Design • Phase I, open-label, dose-escalation and expansion study of ZL-1310 as monotherapy and in combination with atezolizumab or atezolizumab and carboplatin in ES-SCLC (NCT06179069) • Data reported here are all from monotherapy. Data cutoff was February 9, 2026, with a median follow-up tim
Slide 13: Prevalent baseline brain metastasis in pretreated ES-SCLC population
Prevalent baseline brain metastasis in pretreated ES-SCLC population • 136 patients were treated, with majority in 1.2-2.0 mg/kg dose levels. • BM were present in 49 (36%) of patients, including 18 patients with untreated BM. 13
Slide 14: ZL-1310 demonstrated significant intracranial lesion regression
ZL-1310 demonstrated significant intracranial lesion regression as assessed by blind independent review • In all patients with BM, and the opportunity to finish at least two post-baseline scans, intracranial ORR was 53.7% (22/41), and intracranial DCR was 68.3% (28/41) using mRANO-BM by BICR. • Intr
Slide 15: Intracranial responses were durable in responding patients
Intracranial responses were durable in responding patients • Responses occurred rapidly after treatment initiation, with 21 out of the total 22 responders achieving their response at the first post-baseline tumor assessment. • Intracranial response was durable. 14 responders were censored at data cu
Slide 16: Case Studies
Case Studies Intracranial complete & durable partial responses in untreated brain metastases Case 1: 67-year-old female with extensive-stage SCLC • First-line regimen: Etoposide + Carboplatin + Durvalumab + Tarlatamab. • BM developed during the first-line treatment. • No prior radiation to the brain
Slide 17: ZL-1310 demonstrated a manageable safety profile
ZL-1310 demonstrated a manageable safety profile, with TEAEs consistent with the mechanism of a Topo-1 inhibitor ADC • Most TEAEs were low grade, and discontinuation due to TEAEs occurred in low percentage of patients. • The most common grade ≥3 TEAEs included: neutropenia (10.3%, 14/136), anemia (8
Slide 18: Conclusions
CONCLUSIONS • ZL-1310 demonstrated high intracranial response rate in patients with ES-SCLC and baseline brain metastasis. • Overall confirmed intracranial objective response rate (iORR) was 53.7%; at 1.6 mg/kg, the iORR was 62.5%. • 7 complete responses across all doses (CR rate: 17.1%, 7/41), incl
Slide 19: Ongoing Global Phase 3 DELLEVATE Study in 2L+ ES-SCLC
Pivotal trial design Ongoing Global Phase 3 DELLEVATE Study in 2L+ ES-SCLC Primary endpoints: BICR-ORR, OS Secondary endpoints: PFS, DoR, safety, PROs Eligible Patients Zocilurtatug pelitecan (1.6mpk, Q3W) • Progression following platinum- based regimen • Received 1L platinum, or platinum follow
Slide 20: Today's Agenda
Today’s Agenda Introduction Rafael Amado, M.D. Zocilurtatug Pelitecan (ZL-1310, Zoci) Highlights from AACR 2026 – SCLC and NEC Intracranial Activity of Zoci in SCLC Luis Paz Ares, M.D., Ph.D. Zoci in Neuroendocrine Carcinomas Rohit Thummalapalli, M.D. Zoci Clinical Development Plan Rafael Amado, M.D
Slide 21: Preliminary results from phase 1b/2 study of ZL-1310 in neuroendocrine carcinomas
Preliminary results from the phase 1b/2, open- label, multicenter study of ZL-1310, a DLL3- targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors Rohit Thummalapalli1, Ming Lu2, Alexander Spira3, Amr Mohamed4, Rahul Aggarwal5, Yu Wang6, Namrata Vijayvergia7, Jordi
Slide 22: epNECs Represent an Underserved Opportunity
Zoci: Ep-NEC epNECs Represent an Underserved Opportunity – Expanding Zoci’s Reach Beyond SCLC epNEC – Aggressive and Fast-Growing Limited Treatment Options after Platinum-Based Malignancy with High DLL3 Expression Chemotherapy <15% 7.7mos Etoposide + ORR 41-67%; 1L carboplatin/cisplatin mPFS ~6 mont
Slide 23: Background and study overview
Background and study overview • Zocilurtatug pelitecan (ZL-1310) is a novel DLL3-targeted ADC to deliver a TOPO I inhibitor payload to tumor cells. • Open-label, Single-arm, Multi-center, Phase 1b/2 • Patients with advanced or metastatic epNEC who progressed on or after platinum-based chemotherapy w
Slide 24: Patients were pretreated with prior platinum-based chemotherapy
Patients were pretreated with prior platinum-based chemotherapy and multiple prior systemic therapies Baseline Patient Characteristics Phase 1b n (%) Cohort 1 (N=22) Cohort 2 (N=24) Total(N=46) Age, median (range), years 55.5 (35, 82) 56.5 (27, 79) 56.0 (27, 82) Male 12 (54.5) 18 (75.0) 30 (65.2) Ra
Slide 25: ZL-1310 induced tumor reductions within multiple epNEC subtypes
Treatment with ZL-1310 induced tumor reductions within multiple epNEC subtypes with confirmed responses in pretreated patients • Among response evaluable patients, the overall response rate was 38.2% (13/34) across study cohorts and the overall disease control rate was 55.9% (19/34). • Target tumor
Slide 26: Preliminary durability of ZL-1310
Preliminary durability of ZL-1310 Duration of Response and Treatment Exposure* • Multiple cases of durable treatment response were observed. • Overall follow-up remains immature. • A partial response was observed in one patient previously treated with topotecan; no confirmed responses were observed
Slide 27: No clear association between tumor response and DLL3 expression
Preliminary analysis suggests no clear association between tumor response and DLL3 expression (H-Score) DLL3 Expression by Best Response (n=41) * • DLL3 expression was assessed retrospectively by immunohistochemistry using H-score analysis. • Responses (28.6%, 2/7) were observed in patients with H-
Slide 28: ZL-1310 demonstrated a manageable safety profile
ZL-1310 demonstrated a manageable safety profile with TEAEs consistent with an ADC with Topo-1 inhibitor payload • Phase 1b Grade ≥3 treatment-emergent adverse events occurred in 30.4% of patients; Grade ≥3 TRAEs in 15.2% of patients Summary of Treatment-Emergent Adverse Events — All patients (N=58)
Slide 29: Case Study
CASE STUDY 1 Small cell neuroendocrine carcinoma (unknown origin) • 52-year-old male, initially diagnosed in March 2025 with small cell neuroendocrine carcinoma (unknown origin). • Received first-line cisplatin plus etoposide with best response of PD; treatment discontinued in July 2025. • Initiated
Slide 30: Conclusions
Conclusions • ZL-1310 demonstrated clinically meaningful responses in patients with previously treated epNECs, aggressive malignancies with limited treatment options. • Responses were observed across epNEC tumors of different primary origins. • Observed response rates appear favorable in the context
Slide 31: Today's Agenda
Today’s Agenda Introduction Rafael Amado, M.D. Zocilurtatug Pelitecan (ZL-1310, Zoci) Highlights from AACR 2026 – SCLC and NEC Intracranial Activity of Zoci in SCLC Luis Paz Ares, M.D., Ph.D. Zoci in Neuroendocrine Carcinomas Rohit Thummalapalli, M.D. Zoci Clinical Development Plan Rafael Amado, M.D
Slide 32: Significant potential across SCLC and epNEC; Three pivotal trials by YE
Significant potential across SCLC and epNEC; Three pivotal trials by YE Lines of Clinical Study Regimen Phase I Phase II Phase III / Registrational Therapy Sponsor 2L/3L SCLC Zoci mono DLLEVATE ongoing Interim analysis in 2027 SCLC, all Zoci mono; P1 ongoing Data update in 2H’26 lines + PD-L1 +/- ch
Slide 33: Zoci as An Ideal Backbone for DLL3 TCE Combinations in SCLC
Zoci as An Ideal Backbone for DLL3 TCE Combinations in SCLC The Biology Argument: Why DLL3 ADC + TCE? Why Zoci is the Right ADC Partner? Safety Comparison (2L+ SCLC, Monotherapy) for Zoci Tumor volume Investigational Drugs Currently in Global Pivotal Stage2 to rapidly reduce tumor burden by targeted
Slide 34: Global Phase 1b/2 Combination Studies with DLL3 TCEs
Zoci: Combo Global Phase 1b/2 Combination Studies with DLL3 TCEs Amgen A global Phase 1b study to evaluate the safety and efficacy A global Phase 1b/2, open-label, safety and tolerability trial of zoci in combination with IMDELLTRA® in patients with of obrixtamig in combination with zoci in patients
Slide 35: Today's Agenda
Today’s Agenda Introduction Rafael Amado, M.D. Zocilurtatug Pelitecan (ZL-1310, Zoci) Highlights from AACR 2026 – SCLC and NEC Intracranial Activity of Zoci in SCLC Luis Paz Ares, M.D., Ph.D. Zoci in Neuroendocrine Carcinomas Rohit Thummalapalli, M.D. Zoci Clinical Development Plan Rafael Amado, M.D
Slide 36: ZL-1222, a PD-1-Targeted Potency-reduced IL-12 Immunocytokine
ZL-1222, a PD-1-Targeted Potency-reduced IL-12 Immunocytokine, Overcomes PD-1 Resistance and Enhances Antitumor Immunity with a Favorable Safety Profile Cathy Wang1, Lina Wang1, Xue Wang1, Xinchuan Dai1, Qiuping Ye2, Wilson Peng2, Ziruo Wen1, Lei Wang1, Changwei Lv1, Min Chen1, Donghui Li2, Qidong H
Slide 37: ZL-1222: PD-1-targeted potency-reduced IL-12 immunocytokine
ZL-1222: PD-1-targeted potency-reduced IL-12 immunocytokine overcomes PD-1 resistance with enhanced antitumor immunity & favorable safety Structure of ZL-1222 immunocytokine ZL-1222 to address the limitations of ICB and systemic IL-12 therapy A: αPD-1 vHH ZL-1222 to address the limitations of ICB an
Slide 38: ZL-1222: Enhanced Antitumor Immunity
ZL-1222: Enhanced Antitumor Immunity Dose-dependent antitumor activity of ZL-1222 surrogate ZL-1222 surrogate inhibits the growth of ICB-resistant tumors in the CT26 model correlates with pharmacokinetics EMT6 in BALB/c mice EMT6 in BALB/c mice CT26 in BALB/c mice 3000 3000 140 ZL-1222 surrogate, 1
Slide 39: Discovery of ZL-6201, a Novel LRRC15-targeting ADC
Discovery of ZL-6201, a Novel LRRC15-targeting Antibody Drug Conjugate (ADC) for the Treatment of Sarcomas and Epithelial Solid Tumors He Xu1*, Zengxia Li2, Jiaqing Yi1, Wilson Peng1, Qiuping Ye1, Xinchao Xia2, Lei Wang2, Xinchuan Dai2, Yue Ge2, Donghui Li1, Ziruo Wen2, Changwei Lv2, Xuehuo Zeng1, Q
Slide 40: ZL-6201: a Novel LRRC15-Targeting ADC for Sarcomas and Epithelial Solid Tumors
ZL-6201: a Novel LRRC15-Targeting ADC for Sarcomas and Epithelial Solid Tumors Structure of ZL-6201 LRRC15 is Expressed in a Variety of Solid Tumors with High Unmet Need A B C A: Humanized anti-LRRC15 IgG1 mAb B: Cleavable tripeptide-based linker C: Camptothecin derivative payload, C24 LRRC15 is a
Slide 41: ZL-6201 Demonstrated Potent Anti-Tumor Activity via Direct and Bystander Killing
ZL-6201 Demonstrated Potent Anti-Tumor Activity via Direct and Bystander Killing ZL-6201 Drove Dose-dependent Tumor Growth Inhibition in LRRC15+ Bone and Soft-tissue Sarcoma PDX Models A 2000 SA4109 Chondrosarcoma PDX B 2000 SA3840 Osteosarcoma PDX C SA4033 Leiomyosarcoma PDX LRRC15 is highly expres
Slide 42: Today's Agenda
Today’s Agenda Introduction Rafael Amado, M.D. Zocilurtatug Pelitecan (ZL-1310, Zoci) Highlights from AACR 2026 – SCLC and NEC Intracranial Activity of Zoci in SCLC Luis Paz Ares, M.D., Ph.D. Zoci in Neuroendocrine Carcinomas Rohit Thummalapalli, M.D. Zoci Clinical Development Plan Rafael Amado, M.D